Press Release Description

The Global Exocrine Pancreatic Insufficiency Market to Showase a Growth Rate of 7.2% Due to Surging Pancreatic Disorders

The Global Exocrine Pancreatic Insufficiency Market is projected to grow at a CAGR of 7.2% during the forecast period of 2024-30, cites MarkNtel Advisors in the recent research report. The Global Exocrine Pancreatic Insufficiency (EPI) Market growth has been attributed to the rise in the number of obese & overweight individuals worldwide. Obesity causes exocrine deficit and other pancreatic disorders. Therefore, the high preponderance of obesity enhances the risk for exocrine pancreatic deficiency, leading the consumers to undergo a proper diagnosis and ailment. This subsequently uplifts the requirement for Pancreatic Insufficiency (EPI) treatments.

Moreover, Cystic fibrosis is also among the primary causes behind exocrine pancreatic insufficiency. Thus, the large share of consumers dealing with these health issues across the world is also necessitating the adoption of these therapies to guarantee the functioning of crucial body organs.

Furthermore, the number of geriatric inhabitants across the globe is also expanding. This group of the population is at higher risk of contracting chronic illnesses. Therefore, with the growing older population, there would be a higher demand for effective diagnosis and treatment strategies for exocrine pancreatic insufficiency, uplifting market growth.

Further, growing healthcare expenses globally are leading to the allocation of more aid at healthcare facilities. this is consequently helping in detecting, treating, and administrating patients with chronic conditions more quickly.

This would further ensure greater accessibility to the patients to avail quality healthcare services and treatments immediately, broadening consumer trust and driving market growth during the forecast period, further states the research report “Global Exocrine Pancreatic Insufficiency Market Analysis, 2024”

Global Exocrine Pancreatic Insufficiency (EPI) Market

Global Exocrine Pancreatic Insufficiency Market Segmentation Analysis

Pancreatic Exocrine Replacement Therapies (PERT) Segment Dominated the Global Exocrine Pancreatic Insufficiency Market

Based on the treatment method, the market bifurcates into Pancreatic Exocrine Replacement Therapies (PERT) and Nutritional Therapy. Among them, the Pancreatic Exocrine Replacement Therapies (PERT) have registered substantial growth. There has been a surge in several patients with exocrine pancreatic shortage due to genetic abnormalities & inclination towards unhealthy lifestyles. The surge in pancreatic health is generating the demand for therapeutic solutions that help improve the pancreas’ functioning. Therefore, they are increasingly opting for Pancreatic exocrine replacement therapies (PERT), enhancing their market share. Further, the benefits linked with the usage of PERT therapy would continue to gain the attention of several healthcare providers and patients, potentially driving increased adoption and market growth.  

North America Witnessed Considerable Growth in the Global Exocrine Pancreatic Insufficiency Market

Geographically, North America has emerged as a leader in the Global Exocrine Pancreatic Insufficiency Market. The countries in the region have advanced healthcare facilities that have modern medical equipment. Additionally, the inhabitants residing in these countries are also experiencing a lack of exocrine due to multiple pancreatic disorders. Therefore, individuals in these countries are increasingly opting for the therapies, uplifting market growth. Further, the governing authorities are increasingly allocating funds to upgrade the healthcare infrastructure to boost medical tourism in the country. This would continue to increase the inbound medical tourists within the region, contributing to the market expansion in forthcoming years. 

Competitive Landscape

With strategic initiatives, such as mergers, collaborations, and acquisitions, the leading market players, including AbbVie Inc., Nestlé, Digestive Care, Inc., Alcresta Therapeutics, Inc., Organon group of companies, Vivus LLC, etc., are looking forward to strengthening their market position.

Key Questions Answered in the Research Report

  1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
  2. What are the trends influencing the current scenario of the Global Exocrine Pancreatic Insufficiency Market?
  3. What key factors would propel and impede the industry across the region?
  4. How has the industry been evolving in terms of geography & product adoption?
  5. How has the competition been shaping across various regions?
  6. How has the buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2019-30?
  7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?

Place an order
Only market data will be provided in the excel spreadsheet.

USD 3,700

The report will be delivered in PDF format without printing rights. It is advised for a single user.

USD 4,850

The report will be delivered in PDF format with printing rights. It is advised for up to five users.

USD 6,000

The report will be delivered in PDF format with printing rights and excel sheet. It is advised for companies where multiple users would like to access the report from multiple locations

USD 7,500

Need Assistance?


[email protected]
100% Safe & Secure

Strongest encryption on the website to make your purchase safe and secure